ArticleJournal of hepatocellular carcinoma2026
Stage-Dependent Efficacy of TACE Combined with Tyrosine Kinase and Immune Checkpoint Inhibitors as Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study was designed to compare the efficacy and safety of transarterial chemoembolization (TACE) alone versus TACE combined with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) as conversion therapy for patients with initially unresectable hepatocellular carcinoma (HCC), and to identify which patient populations benefit most from triple combination therapy. Methods: This multicenter retrospective study included 260 patients with initially unresectable HCC treated at 7 centers in China between January 2020 and January 2025. Of these, 150 received triple conversion therapy (TACE + TKI + ICI) and 110 received TACE alone. Inverse probability of treatment weighting (IPTW) was applied to minimize confounding. Overall survival (OS), progression-free survival (PFS), tumor response, conversion hepatectomy rates, and treatment-related adverse events (TRAEs) were compared between the two groups. Results: After IPTW, all standardized mean differences were < 0.10. Triple therapy was associated with significantly longer median OS (31.0 vs 16.5 months; HR 0.51, 95% CI: 0.39-0.68, P < 0.001) and PFS (10.2 vs 5.8 months; HR 0.55, 95% CI: 0.43-0.72, P < 0.001), with benefit maintained after IPTW adjustment. The modified RECIST objective response rate (59.3% vs 29.1%) and conversion hepatectomy rate (34.7% vs 12.7%) were both higher with triple therapy (both P < 0.001). The OS benefit was significant in BCLC stage B (HR 0.37, P < 0.001) and stage C (HR 0.47, P < 0.001) but not stage A (HR 0.78, P = 0.480). Grade 3-4 TRAEs did not differ significantly (30.0% vs 24.5%, P = 0.406). Conclusion: Triple conversion therapy was well tolerated and provided superior efficacy over TACE alone in patients with intermediate- or advanced-stage unresectable HCC. No significant survival difference was detected in early-stage (BCLC stage A) disease, supporting a stage-stratified approach to conversion therapy selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.